Comparison of Different Pulsed Field Ablation Catheters in Atrial Fibrillation

Phase

N/A

Condition

Chest Pain

Cardiac Disease

Arrhythmia

Treatment

CardiPulse

FaraPulse

Clinical Study ID

NCT07036965

CP-IIS-007

Ages > 118
All Genders

Study Summary

Pulsed field energy ablation, a non-thermal ablation modality, can potentially reduce post-ablation tissue edema. Previous studies have confirmed the feasibility and safety of combined pulsed field ablation (PFA) and left atrial appendage closure (LAAC) as a one-stop treatment, with few reports of post-ablation tissue edema. However, during PFA procedures, the presence of metallic components in the ablation site (e.g., occluder frames, metallic valves) may lead to arcing during energy delivery, compromising procedural safety. Therefore, when performing PFA+LAAC as a one-stop procedure, a "ablation-first" strategy is recommended. Due to the influence of parameters such as voltage, pulse width, and number of cycles on pulsed field energy characteristics, significant variability in ablation depth and area may exist between different PFA devices. To date, no large-scale clinical studies have compared the efficacy and safety of different PFA systems. Accordingly, this study will conduct a prospective, multicenter, randomized controlled trial to compare the effectiveness and safety of domestic versus imported pulsed field ablation catheters in the treatment of patients with atrial fibrillation.

Eligibility Criteria

Inclusion

Inclusion Criteria:

Older than 18 years.
Diagnosed with drug-refractory, symptomatic atrial fibrillation.
The patient has a high risk of stroke (CHA2DS2-VA score ≥ 2).
Have a situation of:
requires oral anticoagulation therapy
high bleeding risk (HAS-BLED score ≥ 3) that unsuitable for or unwilling toundergo long-term oral anticoagulation therapy.
Subjects are able to understand the purpose of the study, voluntarily participate inthe study and sign the informed consent, and are willing to complete the follow-upaccording to the requirements of the program.

Exclusion

Exclusion Criteria:

History of persistent atrial fibrillation >1 year.
Atrial fibrillation was secondary to thyroid disease or other reversible reasons.
Left atrial anteroposterior diameter >50 mm.
Evidence of left atrial or left atrial appendage thrombus on imaging examination.
Concurrent other arrhythmias required for catheter ablation (e.g., atrioventricularreentrant tachycardia, atrioventricular nodal reentrant tachycardia, pre-excitationsyndrome) prior to enrollment.
Rheumatic heart disease.
Left ventricular ejection fraction <40% or New York Heart Association (NYHA) classIII/IV.
Unstable angina.
Myocardial infarction (MI), coronary artery bypass grafting (CABG), or percutaneouscoronary intervention (PCI) within 3 months prior to enrollment.
History of prior left atrial appendage closure, patent foramen ovale closure, atrialseptal defect closure, or repair surgery.
Implantation of a mechanical mitral valve prosthesis or metallic annuloplasty rings.
Presence of intracardiac thrombus, space-occupying lesions, or other abnormalitiesthat preclude vascular access or catheter manipulation.
Contraindications to anticoagulation or history of coagulation disorders/abnormalbleeding.
Active systemic infection.
Estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m² or history of renaldialysis.
Pregnancy or breastfeeding.
Life expectancy <12 months (e.g., advanced malignancy).
Current or anticipated participation in other drug or device clinical trials.
Any other condition or abnormality deemed by the investigator to warrant exclusion.

Study Design

CardiPulse

June 30, 2025

June 30, 2031

Connect with a study center

Ningbo First Hospital
Hangzhou,
China
Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.